@article{c694d4810ed9490fadb3ff2bac39945d,
title = "The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers",
abstract = "Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the {\textquoteleft}Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls{\textquoteright} (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2). Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge. Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time. Conclusion: This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.",
keywords = "BRCA1, BRCA2, genetic screening, prostate cancer, psychosocial, quality of life",
author = "{IMPACT Study Steering Committee; IMPACT Collaborators} and Bancroft, {Elizabeth K.} and Page, {Elizabeth C.} and Brook, {Mark N.} and Jennifer Pope and Sarah Thomas and Kathryn Myhill and Helfand, {Brian T.} and Pooja Talaty and Ong, {Kai Ren} and Emma Douglas and Jackie Cook and Rosario, {Derek J.} and Monica Salinas and Buys, {Saundra S.} and Jo Anson and Rosemarie Davidson and Mark Longmuir and Lucy Side and Eccles, {Diana M.} and Marc Tischkowitz and Amy Taylor and Mara Cruellas and Ballestero, {Eduard Perez} and Ruth Cleaver and Mohini Varughese and Julian Barwell and Mandy LeButt and Lynn Greenhalgh and Rachel Hart and Ashraf Azzabi and Irene Jobson and Lynn Cogley and Evans, {D. Gareth} and Jeanette Rothwell and Natalie Taylor and Matthew Hogben and Sibel Saya and Zsofia Kote-Jarai and Audrey Ardern-Jones and Chris Bangma and Elena Castro and David Dearnaley and Jorunn Eyfjord and Alison Falconer and Christopher Foster and Henrik Gr{\"o}nberg and Hamdy, {Freddie C.} and J{\'o}hannsson, {{\'O}skar {\TH}{\'o}r} and Dan Leibovici and Eitan Friedman",
note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.",
year = "2024",
month = sep,
doi = "10.1111/bju.16432",
language = "אנגלית",
volume = "134",
pages = "484--500",
journal = "BJU International",
issn = "1464-4096",
publisher = "John Wiley and Sons Inc.",
number = "3",
}
